Article | 26-October-2019
Blood centers are in the unique position to evaluate large numbers of blood donations for antigen-negative blood types. The limitations with the use of hemagglutination, however, can be circumvented with red cell genotyping. The reagents used for genotyping are synthesized and can be designed for any of the known blood group antigen single nucleotide polymorphisms that are associated with blood group antigen expression. There is interest in the application of mass-scale red cell genotyping of
Gregory A. Denomme,
Michael J. Schanen
Immunohematology, Volume 31 , ISSUE 2, 69–74
Introduction | 26-October-2019
Margaret A. Keller
Immunohematology, Volume 31 , ISSUE 2, 49–52
Article | 26-October-2019
Automated testing platforms facilitate the introduction of red cell genotyping of patients and blood donors. Fluidic microarray systems, such as Luminex XMAP (Austin, TX), are used in many clinical applications, including HLA and HPA typing. The Progenika ID CORE XT (Progenika Biopharma-Grifols, Bizkaia, Spain) uses this platform to analyze 29 polymorphisms determining 37 antigens in 10 blood group systems. Once DNA has been extracted, processing time is approximately 4 hours. The system is
Mindy Goldman,
Núria Nogués,
Lilian M. Castilho
Immunohematology, Volume 31 , ISSUE 2, 62–68